Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibro

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

20.11.2023 - Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%)The key secondary endpoints assessing symptom reduction, ... Seite 1

Related Keywords

Munich , Bayern , Germany , Planegg , , Dynamic International Prognostic Scoring System , Spleen Volume , Morphosys Chart , Orphosys Kurs , Morphosys Aktie ,

© 2025 Vimarsana